Affluent Medical published preclinical data in the renowned ANNALS OF THORACIC SURGERY confirming the potential of its Epygon mitral valve to restore blood flow and reduce the risk of cardiac insufficiency.
• Preclinical in vivo results published in The Annals of Thoracic Surgery confirm the Epygon mitral valve ability to adapt to the heart while restoring the native-like blood flow.
• Epygon has been designed to replicate the human physiology to allow a better recovery of the left ventricular function minimizing the risk of cardiac insufficiency.
• A first-in-human clinical trial in 15 patients will be initiated in the 2nd semester 2021 and a pivotal study will be initiated in the US and Europe in the 2nd semester 2022.